Clinical trials: Rivaroxaban
Acute Coronary Syndrome
Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)
The purpose of this study is to evaluate the safety of rivaroxaban in patients with recent acute coronary syndrome (ACS) and to assess the ability of rivaroxaban to reduce the occurrence of death, myocardial infarction (heart…
- Trial name
- NCT00402597
- Testing
- Rivaroxaban
- Volunteers
- 3,490 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Atherosclerosis
Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Current oral anti-coagulation for atrial fibrillation is most commonly performed with warfarin. Warfarin is a vitamin K antagonist that has been shown in non-randomized trials to increase vascular calcification.
- Trial name
- NCT02376010
- Testing
- rivaroxaban, Warfarin
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Atrial Fibrillation
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
The primary purpose of this study is to evaluate comparative effectiveness and safety outcomes of therapies to prevent thromboembolic events in patients with nonvalvular atrial fibrillation by using Korean nationwide health…
- Trial name
- NCT03572972
- Testing
- Apixaban, Dabigatran, Rivaroxaban
- Where
- South Korea
- Volunteers
- 64,684 people
- Sponsor
- Pfizer
Anticoagulant-induced Bleeding
DOAC Versus VKA After Cardiac Surgery
Postoperative management of oral anticoagulation is a frequent preoccupation in cardiac surgery, concerning about half of patients.
- Trial name
- DOAC/VKA (NCT04002011)
- Testing
- Warfarin, Dabigatran, Rivaroxaban
- Sponsor
- Laval University
Venous Thromboembolism, Haemorrhage
Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy
Study Objective: To assess the value of Rivaroxaban for the prevention of venous thromboembolism (VTE) after knee arthroscopy (KA) taking the placebo as standard of reference.
- Trial name
- ERIKA (NCT01629381)
- Testing
- Rivaroxaban
- Where
- 9 sites in Italy
- Volunteers
- 500 people
- Sponsor
- University of Padova
Acute Ischemic Stroke, Atrial Fibrillation
Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF
The goal of this clinical trial is to compare the effectiveness between early and late initiation of anticoagulation therapy in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF).
- Trial name
- ASAP (NCT06057467)
- Testing
- Anticoagulation Agents
- Where
- 2 sites in China
- Volunteers
- 2,351 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Coronary Artery Disease, Atrial Fibrillation
Rivaroxaban - Percutaneous Coronary Intervention
We investigated in-vitro the management of intraprocedural anticoagulation in patients requiring immediate percutaneous coronary intervention(PCI) while using regular direct oral anticoagulants(DOACs).
- Trial name
- NCT05541757
- Testing
- In vitro heparin
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Bursa Postgraduate Hospital
Superficial Vein Thrombosis
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban versus fondaparinux in the treatment of superficial vein thrombosis (SVT).
- Trial name
- NCT01499953
- Testing
- Rivaroxaban, Fondaparinux
- Where
- 23 sites in Germany
- Volunteers
- 472 people
- Sponsor
- GWT-TUD GmbH
Traumatic Intracranial Haemorrhage
Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage
Older people falling from a standing height is the most common cause of hospital admission for head injury. Up to 1 in 3 patients admitted are taking a tablet medication which thins the blood, known as an oral anticoagulant.
- Trial name
- RESTARTtlCrH (NCT06322953)
- Testing
- Direct-Acting Oral Anticoagulants (used as per local standard practice)
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,084 people
- Sponsor
- Walton Centre NHS Foundation Trust
Atrial Fibrillation, Osteoarthritis of the Knee
Assays for and Reversal of New Anticoagulants
New anticoagulants are being introduced to replace warfarin. These drugs do not require monitoring and are safer. There is currently no recommended way to reverse these drugs rapidly in the event of undue bleeding or need for…
- Conditions
- Atrial Fibrillation, Osteoarthritis of the Knee, Osteoarthritis of the Hip
- Trial name
- NCT01795781
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- R.P.Herrmann
Acute Ischemic Stroke, Basilar Artery Occlusion
Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)
The aim of this study is to assess the efficacy and safety of endovascular treatment versus medical management in patients with acute basilar artery occlusion with extended time window of 24-72 hours from onset.
- Trial name
- ANGEL-BAO (NCT06101667)
- Testing
- Best medical management, Endovascular treatment
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Beijing Tiantan Hospital
Biological Availability
Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet
Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders. Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood vessels.
- Trial name
- NCT01853800
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cancer, Solid Tumor
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system.
- Conditions
- Cancer, Solid Tumor, Thromboembolism, Cardiovascular Diseases
- Trial name
- CAT_PB (NCT06065592)
- Testing
- Palbociclib, Rivaroxaban, SNP
- Where
- 2 sites in Lebanon
- Volunteers
- 500 people
- Sponsor
- Lebanese University
Atrial Fibrillation
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation
The DaRe2 approach (healthcare Data for pragmatic clinical Research in the NHS - primary 2 secondary) is designed to operationalise efficient, nationwide, primary care approaches for randomised trials embedded within the UK…
- Trial name
- DaRe2THINK (NCT04700826)
- Testing
- Direct Oral Anticoagulants
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- University of Birmingham
Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)
Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis
This is a single-center prospective cohort study of predictive factors related to prognosis of ischemic stroke due to large-artery atherosclerosis.
- Trial name
- NCT04847752
- Testing
- carotid artery stenting, carotid endarterectomy, Aspirin
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Tongji Hospital
Atrial Fibrillation
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
The purpose of this exploratory study is to evaluate the safety of rivaroxaban and uninterrupted vitamin K antagonist (VKA) in adult participants with non-valvular atrial fibrillation (NVAF) who undergo catheter ablation as…
- Trial name
- VENTURE-AF (NCT01729871)
- Testing
- rivaroxaban, uninterrupted vitamin K antagonist (VKA)
- Where
- 44 sites in United States, Belgium and 3 more
- Volunteers
- 253 people
- Sponsor
- Janssen Scientific Affairs, LLC
Healthy
Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
Rivaroxaban is a direct oral anticoagulant that target specifically activated factor X. Bleeding events related to rivaroxaban are the consequence of physiopathologic, pharmacokinetic issues or poisoning.
- Trial name
- RICHAR2 (NCT04767776)
- Testing
- Rivaroxaban, Activated charcoal
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Total Knee Arthroplasty, Venous Thromboembolism
Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
Yes. For these two fields, I would enter the following in English, based on your study protocol. 1. Brief Summary Copy and paste: This study aims to compare three thromboprophylaxis regimens in adults undergoing primary total…
- Trial name
- DOLOTHROK (NCT07869615)
- Testing
- Apixaban, Rivaroxaban, Enoxaparin (LMWH)
- Where
- Tunisia
- Volunteers
- 138 people
- Sponsor
- Military Hospital of Tunis
Healthy Volunteers
Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
This study is researching experimental drugs called REGN9933 and REGN7508 (called "study drugs") and comparing their effects to approved treatments of rivaroxaban and aspirin (called "standard treatments").
- Trial name
- NCT06444178
- Testing
- Aspirin, REGN9933, REGN7508
- Where
- United Kingdom
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals